AU6932198A - Cox-2 selective carprofen for treating pain and inflammation in dogs - Google Patents

Cox-2 selective carprofen for treating pain and inflammation in dogs Download PDF

Info

Publication number: AU6932198A
Authority: AU; Australia
Prior art keywords: cox; carprofen; inhibitors; inflammatory; inhibition
Prior art date: 1997-05-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU69321/98A

Other languages

English (en)

Inventor

Kristin Marie Lundy

Anthony Paul Ricketts

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pfizer Corp SRL

Original Assignee

Pfizer Corp Belgium

Pfizer Corp SRL

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-05-05

Filing date

1998-05-01

Publication date

1998-11-27

1998-05-01 Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium

1998-11-27 Publication of AU6932198A publication Critical patent/AU6932198A/en

2002-05-08 Priority to AU38232/02A priority Critical patent/AU773615B2/en

Status Abandoned legal-status Critical Current

Links

229960003184 carprofen Drugs 0.000 title claims description 249
241000282472 Canis lupus familiaris Species 0.000 title claims description 195
230000004054 inflammatory process Effects 0.000 title claims description 119
206010061218 Inflammation Diseases 0.000 title claims description 96
208000002193 Pain Diseases 0.000 title claims description 68
IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 title claims 9
101150071146 COX2 gene Proteins 0.000 title description 6
101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 title description 5
101150000187 PTGS2 gene Proteins 0.000 title description 5
108010037462 Cyclooxygenase 2 Proteins 0.000 claims description 237
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims description 229
239000003112 inhibitor Substances 0.000 claims description 166
230000005764 inhibitory process Effects 0.000 claims description 141
239000002552 dosage form Substances 0.000 claims description 119
150000001875 compounds Chemical class 0.000 claims description 114
108010037464 Cyclooxygenase 1 Proteins 0.000 claims description 112
230000000694 effects Effects 0.000 claims description 112
102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 claims description 110
239000000203 mixture Substances 0.000 claims description 100
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 98
230000003110 anti-inflammatory effect Effects 0.000 claims description 80
239000003814 drug Substances 0.000 claims description 74
238000013270 controlled release Methods 0.000 claims description 73
238000000034 method Methods 0.000 claims description 62
230000002401 inhibitory effect Effects 0.000 claims description 60
239000008194 pharmaceutical composition Substances 0.000 claims description 53
239000007787 solid Substances 0.000 claims description 46
-1 amino, hydroxyamino Chemical group 0.000 claims description 42
239000004480 active ingredient Substances 0.000 claims description 36
239000007788 liquid Substances 0.000 claims description 36
238000011282 treatment Methods 0.000 claims description 35
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 33
239000007943 implant Substances 0.000 claims description 30
210000004369 blood Anatomy 0.000 claims description 29
239000008280 blood Substances 0.000 claims description 29
239000000839 emulsion Substances 0.000 claims description 29
201000010099 disease Diseases 0.000 claims description 26
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
238000002347 injection Methods 0.000 claims description 25
239000007924 injection Substances 0.000 claims description 25
125000000217 alkyl group Chemical group 0.000 claims description 23
239000000243 solution Substances 0.000 claims description 23
238000001802 infusion Methods 0.000 claims description 21
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 21
229940124597 therapeutic agent Drugs 0.000 claims description 21
150000003839 salts Chemical group 0.000 claims description 19
239000000725 suspension Substances 0.000 claims description 19
238000009472 formulation Methods 0.000 claims description 18
230000009885 systemic effect Effects 0.000 claims description 18
239000002464 receptor antagonist Substances 0.000 claims description 17
229940044551 receptor antagonist Drugs 0.000 claims description 17
239000003826 tablet Substances 0.000 claims description 17
239000002775 capsule Substances 0.000 claims description 16
239000003795 chemical substances by application Substances 0.000 claims description 16
230000001939 inductive effect Effects 0.000 claims description 16
125000001309 chloro group Chemical group Cl* 0.000 claims description 15
238000007910 systemic administration Methods 0.000 claims description 15
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 14
238000012384 transportation and delivery Methods 0.000 claims description 14
210000002784 stomach Anatomy 0.000 claims description 13
125000003282 alkyl amino group Chemical group 0.000 claims description 12
229910052799 carbon Inorganic materials 0.000 claims description 12
125000001153 fluoro group Chemical group F* 0.000 claims description 12
239000007935 oral tablet Substances 0.000 claims description 12
230000002757 inflammatory effect Effects 0.000 claims description 11
150000002617 leukotrienes Chemical class 0.000 claims description 11
239000000463 material Substances 0.000 claims description 10
239000002207 metabolite Substances 0.000 claims description 10
239000000651 prodrug Substances 0.000 claims description 10
229940002612 prodrug Drugs 0.000 claims description 10
230000001225 therapeutic effect Effects 0.000 claims description 9
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 8
239000005541 ACE inhibitor Substances 0.000 claims description 8
239000000867 Lipoxygenase Inhibitor Substances 0.000 claims description 8
239000003995 emulsifying agent Substances 0.000 claims description 8
238000013268 sustained release Methods 0.000 claims description 8
125000006526 (C1-C2) alkyl group Chemical group 0.000 claims description 7
239000000674 adrenergic antagonist Substances 0.000 claims description 7
238000001361 intraarterial administration Methods 0.000 claims description 7
238000007918 intramuscular administration Methods 0.000 claims description 7
238000007913 intrathecal administration Methods 0.000 claims description 7
238000001990 intravenous administration Methods 0.000 claims description 7
239000008297 liquid dosage form Substances 0.000 claims description 7
239000012730 sustained-release form Substances 0.000 claims description 7
238000010521 absorption reaction Methods 0.000 claims description 6
125000003545 alkoxy group Chemical group 0.000 claims description 6
235000013305 food Nutrition 0.000 claims description 6
230000037406 food intake Effects 0.000 claims description 6
229910052736 halogen Inorganic materials 0.000 claims description 6
210000004072 lung Anatomy 0.000 claims description 6
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
230000008569 process Effects 0.000 claims description 6
239000007909 solid dosage form Substances 0.000 claims description 6
239000000375 suspending agent Substances 0.000 claims description 6
208000024891 symptom Diseases 0.000 claims description 6
239000013543 active substance Substances 0.000 claims description 5
239000000730 antalgic agent Substances 0.000 claims description 5
239000012141 concentrate Substances 0.000 claims description 5
238000009826 distribution Methods 0.000 claims description 5
150000002367 halogens Chemical class 0.000 claims description 5
230000018984 mastication Effects 0.000 claims description 5
238000010077 mastication Methods 0.000 claims description 5
229940096978 oral tablet Drugs 0.000 claims description 5
238000003860 storage Methods 0.000 claims description 5
238000007920 subcutaneous administration Methods 0.000 claims description 5
239000000829 suppository Substances 0.000 claims description 5
LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims description 4
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 4
208000000044 Amnesia Diseases 0.000 claims description 4
206010002383 Angina Pectoris Diseases 0.000 claims description 4
102000005862 Angiotensin II Human genes 0.000 claims description 4
101800000733 Angiotensin-2 Proteins 0.000 claims description 4
229940127291 Calcium channel antagonist Drugs 0.000 claims description 4
206010007559 Cardiac failure congestive Diseases 0.000 claims description 4
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 4
108010036949 Cyclosporine Proteins 0.000 claims description 4
229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 4
206010019280 Heart failures Diseases 0.000 claims description 4
206010020772 Hypertension Diseases 0.000 claims description 4
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 4
208000026139 Memory disease Diseases 0.000 claims description 4
108700023400 Platelet-activating factor receptors Proteins 0.000 claims description 4
102000008866 Prostaglandin E receptors Human genes 0.000 claims description 4
108010088540 Prostaglandin E receptors Proteins 0.000 claims description 4
239000000219 Sympatholytic Substances 0.000 claims description 4
229940116731 Uricosuric agent Drugs 0.000 claims description 4
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 4
229940122803 Vinca alkaloid Drugs 0.000 claims description 4
239000000048 adrenergic agonist Substances 0.000 claims description 4
229960003459 allopurinol Drugs 0.000 claims description 4
OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims description 4
229940035676 analgesics Drugs 0.000 claims description 4
229940035674 anesthetics Drugs 0.000 claims description 4
239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 4
229950006323 angiotensin ii Drugs 0.000 claims description 4
230000000843 anti-fungal effect Effects 0.000 claims description 4
230000000326 anti-hypercholesterolaemic effect Effects 0.000 claims description 4
230000003276 anti-hypertensive effect Effects 0.000 claims description 4
230000000842 anti-protozoal effect Effects 0.000 claims description 4
230000000840 anti-viral effect Effects 0.000 claims description 4
229940121375 antifungal agent Drugs 0.000 claims description 4
239000002255 antigout agent Substances 0.000 claims description 4
229960002708 antigout preparations Drugs 0.000 claims description 4
229940030600 antihypertensive agent Drugs 0.000 claims description 4
239000002220 antihypertensive agent Substances 0.000 claims description 4
239000003080 antimitotic agent Substances 0.000 claims description 4
229940034982 antineoplastic agent Drugs 0.000 claims description 4
239000002246 antineoplastic agent Substances 0.000 claims description 4
239000003904 antiprotozoal agent Substances 0.000 claims description 4
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 4
229960002170 azathioprine Drugs 0.000 claims description 4
WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 claims description 4
229960002529 benzbromarone Drugs 0.000 claims description 4
230000003115 biocidal effect Effects 0.000 claims description 4
239000000480 calcium channel blocker Substances 0.000 claims description 4
239000007894 caplet Substances 0.000 claims description 4
239000002327 cardiovascular agent Substances 0.000 claims description 4
229940125692 cardiovascular agent Drugs 0.000 claims description 4
229960001265 ciclosporin Drugs 0.000 claims description 4
230000001149 cognitive effect Effects 0.000 claims description 4
229960001338 colchicine Drugs 0.000 claims description 4
229930182912 cyclosporin Natural products 0.000 claims description 4
230000006735 deficit Effects 0.000 claims description 4
239000002934 diuretic Substances 0.000 claims description 4
229940030606 diuretics Drugs 0.000 claims description 4
239000002792 enkephalinase inhibitor Substances 0.000 claims description 4
239000002662 enteric coated tablet Substances 0.000 claims description 4
230000002178 gastroprotective effect Effects 0.000 claims description 4
239000003193 general anesthetic agent Substances 0.000 claims description 4
239000003862 glucocorticoid Substances 0.000 claims description 4
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 4
239000010931 gold Substances 0.000 claims description 4
229910052737 gold Inorganic materials 0.000 claims description 4
239000003324 growth hormone secretagogue Substances 0.000 claims description 4
229940077716 histamine h2 receptor antagonists for peptic ulcer and gord Drugs 0.000 claims description 4
XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 4
229960004171 hydroxychloroquine Drugs 0.000 claims description 4
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 4
229940125721 immunosuppressive agent Drugs 0.000 claims description 4
239000003018 immunosuppressive agent Substances 0.000 claims description 4
238000002386 leaching Methods 0.000 claims description 4
239000007937 lozenge Substances 0.000 claims description 4
230000006984 memory degeneration Effects 0.000 claims description 4
206010027175 memory impairment Diseases 0.000 claims description 4
208000023060 memory loss Diseases 0.000 claims description 4
229960000485 methotrexate Drugs 0.000 claims description 4
208000010125 myocardial infarction Diseases 0.000 claims description 4
208000031225 myocardial ischemia Diseases 0.000 claims description 4
229940041667 oral paste Drugs 0.000 claims description 4
229960001639 penicillamine Drugs 0.000 claims description 4
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims description 4
102000030769 platelet activating factor receptor Human genes 0.000 claims description 4
DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 claims description 4
229960003081 probenecid Drugs 0.000 claims description 4
239000002089 prostaglandin antagonist Substances 0.000 claims description 4
239000002461 renin inhibitor Substances 0.000 claims description 4
229940086526 renin-inhibitors Drugs 0.000 claims description 4
MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 claims description 4
229960003329 sulfinpyrazone Drugs 0.000 claims description 4
238000012385 systemic delivery Methods 0.000 claims description 4
229940037128 systemic glucocorticoids Drugs 0.000 claims description 4
DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 claims description 4
239000003383 uricosuric agent Substances 0.000 claims description 4
229940124549 vasodilator Drugs 0.000 claims description 4
239000003071 vasodilator agent Substances 0.000 claims description 4
229960003048 vinblastine Drugs 0.000 claims description 4
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 4
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 4
229960004528 vincristine Drugs 0.000 claims description 4
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 4
239000003064 xanthine oxidase inhibitor Substances 0.000 claims description 4
201000001320 Atherosclerosis Diseases 0.000 claims description 3
241000894006 Bacteria Species 0.000 claims description 3
108010073099 Epoprostenol Receptors Proteins 0.000 claims description 3
241000233866 Fungi Species 0.000 claims description 3
241000700605 Viruses Species 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
239000000284 extract Substances 0.000 claims description 3
230000002265 prevention Effects 0.000 claims description 3
208000011580 syndromic disease Diseases 0.000 claims description 3
239000012678 infectious agent Substances 0.000 claims description 2
229940100692 oral suspension Drugs 0.000 claims description 2
229940059096 powder for oral suspension Drugs 0.000 claims description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
102000009079 Epoprostenol Receptors Human genes 0.000 claims 2
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims 2
239000000612 proton pump inhibitor Substances 0.000 claims 2
229940126409 proton pump inhibitor Drugs 0.000 claims 2
XEDSZIKWEGZUTC-UHFFFAOYSA-N 2-(9h-carbazol-2-yl)acetic acid Chemical compound C1=CC=C2C3=CC=C(CC(=O)O)C=C3NC2=C1 XEDSZIKWEGZUTC-UHFFFAOYSA-N 0.000 claims 1
230000002924 anti-infective effect Effects 0.000 claims 1
239000007950 delayed release tablet Substances 0.000 claims 1
PUXBGTOOZJQSKH-UHFFFAOYSA-N carprofen Chemical compound C1=C(Cl)C=C2C3=CC=C(C(C(O)=O)C)C=C3NC2=C1 PUXBGTOOZJQSKH-UHFFFAOYSA-N 0.000 description 248
108010044467 Isoenzymes Proteins 0.000 description 56
210000002381 plasma Anatomy 0.000 description 48
229940079593 drug Drugs 0.000 description 47
241000282465 Canis Species 0.000 description 35
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 33
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 33
230000036470 plasma concentration Effects 0.000 description 28
239000002253 acid Substances 0.000 description 26
230000002496 gastric effect Effects 0.000 description 25
238000012360 testing method Methods 0.000 description 25
150000003180 prostaglandins Chemical class 0.000 description 24
210000001519 tissue Anatomy 0.000 description 23
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 22
229940111134 coxibs Drugs 0.000 description 22
230000009471 action Effects 0.000 description 21
239000012729 immediate-release (IR) formulation Substances 0.000 description 21
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
239000012071 phase Substances 0.000 description 20
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 19
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 19
229940094443 oxytocics prostaglandins Drugs 0.000 description 19
150000007513 acids Chemical class 0.000 description 18
239000002260 anti-inflammatory agent Substances 0.000 description 17
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
241000282412 Homo Species 0.000 description 15
229940121363 anti-inflammatory agent Drugs 0.000 description 15
238000004519 manufacturing process Methods 0.000 description 15
238000000338 in vitro Methods 0.000 description 14
241000894007 species Species 0.000 description 14
230000002411 adverse Effects 0.000 description 13
230000015572 biosynthetic process Effects 0.000 description 13
238000006243 chemical reaction Methods 0.000 description 13
230000000875 corresponding effect Effects 0.000 description 13
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 12
229940124639 Selective inhibitor Drugs 0.000 description 12
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
239000002158 endotoxin Substances 0.000 description 12
201000008482 osteoarthritis Diseases 0.000 description 12
102000004190 Enzymes Human genes 0.000 description 11
108090000790 Enzymes Proteins 0.000 description 11
229940114079 arachidonic acid Drugs 0.000 description 11
235000021342 arachidonic acid Nutrition 0.000 description 11
230000037396 body weight Effects 0.000 description 11
229920006008 lipopolysaccharide Polymers 0.000 description 11
241001465754 Metazoa Species 0.000 description 10
235000011054 acetic acid Nutrition 0.000 description 10
239000002585 base Substances 0.000 description 10
230000007246 mechanism Effects 0.000 description 10
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
206010067484 Adverse reaction Diseases 0.000 description 9
241000282414 Homo sapiens Species 0.000 description 9
230000006838 adverse reaction Effects 0.000 description 9
238000003556 assay Methods 0.000 description 9
210000001772 blood platelet Anatomy 0.000 description 9
125000002843 carboxylic acid group Chemical group 0.000 description 9
230000003111 delayed effect Effects 0.000 description 9
229960002390 flurbiprofen Drugs 0.000 description 9
SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 9
229960000905 indomethacin Drugs 0.000 description 9
238000002560 therapeutic procedure Methods 0.000 description 9
241000700159 Rattus Species 0.000 description 8
230000027455 binding Effects 0.000 description 8
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
210000004027 cell Anatomy 0.000 description 8
125000004356 hydroxy functional group Chemical group O* 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
238000011835 investigation Methods 0.000 description 8
210000003491 skin Anatomy 0.000 description 8
OYZKFVIVPRQRQQ-UHFFFAOYSA-N 1-phenylsulfonamide-3-trifluoromethyl-5-parabromophenylpyrazole Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC(Br)=CC=2)=CC(C(F)(F)F)=N1 OYZKFVIVPRQRQQ-UHFFFAOYSA-N 0.000 description 7
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 7
238000011156 evaluation Methods 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
238000003786 synthesis reaction Methods 0.000 description 7
PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical class NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
230000000202 analgesic effect Effects 0.000 description 6
RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 6
230000004071 biological effect Effects 0.000 description 6
239000000679 carrageenan Substances 0.000 description 6
235000010418 carrageenan Nutrition 0.000 description 6
229920001525 carrageenan Polymers 0.000 description 6
229940113118 carrageenan Drugs 0.000 description 6
239000003651 drinking water Substances 0.000 description 6
235000020188 drinking water Nutrition 0.000 description 6
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 6
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 6
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 6
229960000991 ketoprofen Drugs 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 6
239000006186 oral dosage form Substances 0.000 description 6
230000003389 potentiating effect Effects 0.000 description 6
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
231100001274 therapeutic index Toxicity 0.000 description 6
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 6
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
102000000589 Interleukin-1 Human genes 0.000 description 5
108010002352 Interleukin-1 Proteins 0.000 description 5
SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 5
BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 5
PDODBKYPSUYQGT-UHFFFAOYSA-N acetic acid;1h-indene Chemical class CC(O)=O.C1=CC=C2CC=CC2=C1 PDODBKYPSUYQGT-UHFFFAOYSA-N 0.000 description 5
239000011159 matrix material Substances 0.000 description 5
210000004877 mucosa Anatomy 0.000 description 5
229960004270 nabumetone Drugs 0.000 description 5
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 5
229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 5
150000003872 salicylic acid derivatives Chemical class 0.000 description 5
239000000126 substance Substances 0.000 description 5
KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical group NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
208000017667 Chronic Disease Diseases 0.000 description 4
108010061435 Enalapril Proteins 0.000 description 4
208000032843 Hemorrhage Diseases 0.000 description 4
RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 4
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 4
102000003820 Lipoxygenases Human genes 0.000 description 4
108090000128 Lipoxygenases Proteins 0.000 description 4
ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 4
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 4
208000004550 Postoperative Pain Diseases 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 4
229960001138 acetylsalicylic acid Drugs 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 4
239000000872 buffer Substances 0.000 description 4
238000011260 co-administration Methods 0.000 description 4
230000006378 damage Effects 0.000 description 4
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 4
229960002986 dinoprostone Drugs 0.000 description 4
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 4
229960000873 enalapril Drugs 0.000 description 4
230000006870 function Effects 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
229960001680 ibuprofen Drugs 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
229960003803 meclofenamic acid Drugs 0.000 description 4
229960001929 meloxicam Drugs 0.000 description 4
229960002009 naproxen Drugs 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
239000008177 pharmaceutical agent Substances 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
229960002895 phenylbutazone Drugs 0.000 description 4
239000008363 phosphate buffer Substances 0.000 description 4
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 4
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
230000000707 stereoselective effect Effects 0.000 description 4
XNRNNGPBEPRNAR-JQBLCGNGSA-N thromboxane B2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1OC(O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O XNRNNGPBEPRNAR-JQBLCGNGSA-N 0.000 description 4
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
239000004475 Arginine Substances 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
239000005711 Benzoic acid Substances 0.000 description 3
108091006146 Channels Proteins 0.000 description 3
208000000094 Chronic Pain Diseases 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
KTDZCOWXCWUPEO-UHFFFAOYSA-N NS-398 Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1CCCCC1 KTDZCOWXCWUPEO-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
XNRNNGPBEPRNAR-UHFFFAOYSA-N Thromboxane B2 Natural products CCCCCC(O)C=CC1OC(O)CC(O)C1CC=CCCCC(O)=O XNRNNGPBEPRNAR-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
208000025865 Ulcer Diseases 0.000 description 3
ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 3
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
235000010233 benzoic acid Nutrition 0.000 description 3
QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 3
230000036760 body temperature Effects 0.000 description 3
239000003710 calcium ionophore Substances 0.000 description 3
HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 description 3
150000003857 carboxamides Chemical class 0.000 description 3
150000007942 carboxylates Chemical group 0.000 description 3
230000008859 change Effects 0.000 description 3
230000002596 correlated effect Effects 0.000 description 3
230000002354 daily effect Effects 0.000 description 3
229960001259 diclofenac Drugs 0.000 description 3
150000002066 eicosanoids Chemical class 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
210000002615 epidermis Anatomy 0.000 description 3
CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 3
229960005293 etodolac Drugs 0.000 description 3
XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 3
210000000416 exudates and transudate Anatomy 0.000 description 3
238000001914 filtration Methods 0.000 description 3
125000001072 heteroaryl group Chemical group 0.000 description 3
238000003018 immunoassay Methods 0.000 description 3
230000001976 improved effect Effects 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
208000027866 inflammatory disease Diseases 0.000 description 3
230000003993 interaction Effects 0.000 description 3
210000000936 intestine Anatomy 0.000 description 3
238000007919 intrasynovial administration Methods 0.000 description 3
OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 3
229960004752 ketorolac Drugs 0.000 description 3
239000008101 lactose Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
229960003464 mefenamic acid Drugs 0.000 description 3
HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 3
210000000440 neutrophil Anatomy 0.000 description 3
HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 3
229960000965 nimesulide Drugs 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 3
229960002702 piroxicam Drugs 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
230000004044 response Effects 0.000 description 3
239000002904 solvent Substances 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
229940124530 sulfonamide Drugs 0.000 description 3
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
210000001179 synovial fluid Anatomy 0.000 description 3
230000001839 systemic circulation Effects 0.000 description 3
YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 3
230000036269 ulceration Effects 0.000 description 3
RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 2
YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 2
CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 2
BVNJBATUHVXZKP-QXMHVHEDSA-N (3z)-6-chloro-5-fluoro-3-[hydroxy(thiophen-2-yl)methylidene]-2-oxoindole-1-carboxamide Chemical compound C12=CC(F)=C(Cl)C=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 BVNJBATUHVXZKP-QXMHVHEDSA-N 0.000 description 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 2
HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 2
VZUGVMQFWFVFBX-UHFFFAOYSA-N 2-(4-cyclohexyl-1-naphthyl)propanoic acid Chemical compound C12=CC=CC=C2C(C(C(O)=O)C)=CC=C1C1CCCCC1 VZUGVMQFWFVFBX-UHFFFAOYSA-N 0.000 description 2
UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
YZXBAPSDXZZRGB-DOFZRALJSA-M Arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O YZXBAPSDXZZRGB-DOFZRALJSA-M 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
208000035143 Bacterial infection Diseases 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
239000002083 C09CA01 - Losartan Substances 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
101710129448 Glucose-6-phosphate isomerase 2 Proteins 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
206010027727 Mitral valve incompetence Diseases 0.000 description 2
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
241001529936 Murinae Species 0.000 description 2
JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
241000700157 Rattus norvegicus Species 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
101000942305 Zea mays Cytokinin dehydrogenase 1 Proteins 0.000 description 2
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 2
208000005298 acute pain Diseases 0.000 description 2
229960005142 alclofenac Drugs 0.000 description 2
125000002877 alkyl aryl group Chemical group 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
239000003708 ampul Substances 0.000 description 2
229940124599 anti-inflammatory drug Drugs 0.000 description 2
230000001754 anti-pyretic effect Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
229940114078 arachidonate Drugs 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
208000022362 bacterial infectious disease Diseases 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
239000011575 calcium Substances 0.000 description 2
239000007963 capsule composition Substances 0.000 description 2
150000001721 carbon Chemical group 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 2
230000006020 chronic inflammation Effects 0.000 description 2
208000037976 chronic inflammation Diseases 0.000 description 2
229960002896 clonidine Drugs 0.000 description 2
238000004737 colorimetric analysis Methods 0.000 description 2
208000016569 congenital mitral valve insufficiency Diseases 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
230000001120 cytoprotective effect Effects 0.000 description 2
230000007423 decrease Effects 0.000 description 2
229940033108 delayed release oral tablet Drugs 0.000 description 2
238000011161 development Methods 0.000 description 2
HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
230000003292 diminished effect Effects 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000001035 drying Methods 0.000 description 2
230000005284 excitation Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
229960000192 felbinac Drugs 0.000 description 2
229960004369 flufenamic acid Drugs 0.000 description 2
LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 2
239000012530 fluid Substances 0.000 description 2
NOOCSNJCXJYGPE-UHFFFAOYSA-N flunixin Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O NOOCSNJCXJYGPE-UHFFFAOYSA-N 0.000 description 2
MGCCHNLNRBULBU-WZTVWXICSA-N flunixin meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O MGCCHNLNRBULBU-WZTVWXICSA-N 0.000 description 2
210000001156 gastric mucosa Anatomy 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
230000036541 health Effects 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
229960002474 hydralazine Drugs 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
229950011445 ilonidap Drugs 0.000 description 2
238000011534 incubation Methods 0.000 description 2
229960004187 indoprofen Drugs 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
208000014674 injury Diseases 0.000 description 2
230000007794 irritation Effects 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
QFGMXJOBTNZHEL-UHFFFAOYSA-N isoxepac Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC(CC(=O)O)=CC=C21 QFGMXJOBTNZHEL-UHFFFAOYSA-N 0.000 description 2
210000001503 joint Anatomy 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
229960004773 losartan Drugs 0.000 description 2
KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 2
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
229960004844 lovastatin Drugs 0.000 description 2
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
231100000682 maximum tolerated dose Toxicity 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000010534 mechanism of action Effects 0.000 description 2
238000002483 medication Methods 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
244000005700 microbiome Species 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
208000005907 mitral valve insufficiency Diseases 0.000 description 2
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
229960001597 nifedipine Drugs 0.000 description 2
229960000916 niflumic acid Drugs 0.000 description 2
239000000014 opioid analgesic Substances 0.000 description 2
229940005483 opioid analgesics Drugs 0.000 description 2
210000004789 organ system Anatomy 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
206010034674 peritonitis Diseases 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
229960003424 phenylacetic acid Drugs 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
229960001289 prazosin Drugs 0.000 description 2
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
150000004672 propanoic acids Chemical class 0.000 description 2
235000019260 propionic acid Nutrition 0.000 description 2
229960003712 propranolol Drugs 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
239000002599 prostaglandin synthase inhibitor Substances 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
239000000376 reactant Substances 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000000758 substrate Substances 0.000 description 2
125000000565 sulfonamide group Chemical group 0.000 description 2
150000003456 sulfonamides Chemical class 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
239000007916 tablet composition Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
229960003676 tenidap Drugs 0.000 description 2
LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 2
UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 2
230000000451 tissue damage Effects 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
229960002905 tolfenamic acid Drugs 0.000 description 2
230000008791 toxic response Effects 0.000 description 2
230000001562 ulcerogenic effect Effects 0.000 description 2
239000004474 valine Substances 0.000 description 2
229950010082 vedaprofen Drugs 0.000 description 2
RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 1
NTGZYEIFZWYKFV-WLDMJGECSA-N (2r,3s,4r,5r)-1-(methylamino)hexane-1,2,3,4,5,6-hexol Chemical compound CNC(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO NTGZYEIFZWYKFV-WLDMJGECSA-N 0.000 description 1
RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
125000006536 (C1-C2)alkoxy group Chemical group 0.000 description 1
ZNHVWPKMFKADKW-UHFFFAOYSA-N 12-HETE Chemical compound CCCCCC=CCC(O)C=CC=CCC=CCCCC(O)=O ZNHVWPKMFKADKW-UHFFFAOYSA-N 0.000 description 1
ZNHVWPKMFKADKW-ZYBDYUKJSA-N 12-HETE Natural products CCCCC\C=C/C[C@@H](O)\C=C\C=C/C\C=C/CCCC(O)=O ZNHVWPKMFKADKW-ZYBDYUKJSA-N 0.000 description 1
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
XKLNOVWDVMWTOB-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1h-carbazole Chemical compound N1C2=CC=CC=C2C2=C1CCCC2 XKLNOVWDVMWTOB-UHFFFAOYSA-N 0.000 description 1
ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
ODZUWQAFWMLWCF-UHFFFAOYSA-N 2-(3-phenyl-1-benzofuran-7-yl)propanoic acid Chemical compound C=1OC=2C(C(C(O)=O)C)=CC=CC=2C=1C1=CC=CC=C1 ODZUWQAFWMLWCF-UHFFFAOYSA-N 0.000 description 1
LOWWSYWGAKCKLG-UHFFFAOYSA-N 2-(6-methoxynaphthalen-1-yl)acetic acid Chemical compound OC(=O)CC1=CC=CC2=CC(OC)=CC=C21 LOWWSYWGAKCKLG-UHFFFAOYSA-N 0.000 description 1
LRXFKKPEBXIPMW-UHFFFAOYSA-N 2-(9h-fluoren-2-yl)propanoic acid Chemical compound C1=CC=C2C3=CC=C(C(C(O)=O)C)C=C3CC2=C1 LRXFKKPEBXIPMW-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
GHNLJDPNIAIWOQ-UHFFFAOYSA-N 2h-1$l^{6},2-benzothiazine 1,1-dioxide Chemical group C1=CC=C2S(=O)(=O)NC=CC2=C1 GHNLJDPNIAIWOQ-UHFFFAOYSA-N 0.000 description 1
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
QSXXLDDWVCEBFP-UHFFFAOYSA-N 7-(ethoxymethyl)-1-(5-hydroxy-5-methylhexyl)-3-methylpurine-2,6-dione Chemical compound CN1C(=O)N(CCCCC(C)(C)O)C(=O)C2=C1N=CN2COCC QSXXLDDWVCEBFP-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101800004538 Bradykinin Proteins 0.000 description 1
102400000967 Bradykinin Human genes 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
229940122204 Cyclooxygenase inhibitor Drugs 0.000 description 1
208000012239 Developmental disease Diseases 0.000 description 1
206010073767 Developmental hip dysplasia Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
206010018001 Gastrointestinal perforation Diseases 0.000 description 1
206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical group NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
208000007446 Hip Dislocation Diseases 0.000 description 1
101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
102100037611 Lysophospholipase Human genes 0.000 description 1
244000062730 Melissa officinalis Species 0.000 description 1
235000010654 Melissa officinalis Nutrition 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
ONXPDKGXOOORHB-BYPYZUCNSA-N N(5)-methyl-L-glutamine Chemical compound CNC(=O)CC[C@H](N)C(O)=O ONXPDKGXOOORHB-BYPYZUCNSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
241001207999 Notaris Species 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
201000009859 Osteochondrosis Diseases 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
102000015439 Phospholipases Human genes 0.000 description 1
108010064785 Phospholipases Proteins 0.000 description 1
108010058864 Phospholipases A2 Proteins 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
102100026476 Prostacyclin receptor Human genes 0.000 description 1
239000004365 Protease Substances 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
241000906446 Theraps Species 0.000 description 1
208000026062 Tissue disease Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
MMBFUKUTZUAQMJ-UHFFFAOYSA-N acetic acid;9h-carbazole Chemical class CC(O)=O.C1=CC=C2C3=CC=CC=C3NC2=C1 MMBFUKUTZUAQMJ-UHFFFAOYSA-N 0.000 description 1
150000001243 acetic acids Chemical class 0.000 description 1
230000009858 acid secretion Effects 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
208000038016 acute inflammation Diseases 0.000 description 1
230000006022 acute inflammation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000001760 anti-analgesic effect Effects 0.000 description 1
230000002456 anti-arthritic effect Effects 0.000 description 1
238000011861 anti-inflammatory therapy Methods 0.000 description 1
239000000883 anti-obesity agent Substances 0.000 description 1
230000009830 antibody antigen interaction Effects 0.000 description 1
229940111133 antiinflammatory and antirheumatic drug oxicams Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
239000003908 antipruritic agent Substances 0.000 description 1
239000003435 antirheumatic agent Substances 0.000 description 1
210000002403 aortic endothelial cell Anatomy 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
238000005899 aromatization reaction Methods 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005370 atorvastatin Drugs 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
229940083741 banamine Drugs 0.000 description 1
RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
229910001863 barium hydroxide Inorganic materials 0.000 description 1
230000006399 behavior Effects 0.000 description 1
229960005430 benoxaprofen Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
238000010256 biochemical assay Methods 0.000 description 1
229920013641 bioerodible polymer Polymers 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
125000004799 bromophenyl group Chemical group 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
239000000920 calcium hydroxide Substances 0.000 description 1
229910001861 calcium hydroxide Inorganic materials 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
230000004856 capillary permeability Effects 0.000 description 1
125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229950002545 cicloprofen Drugs 0.000 description 1
230000004087 circulation Effects 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000010835 comparative analysis Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
210000004207 dermis Anatomy 0.000 description 1
238000001514 detection method Methods 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
229960000616 diflunisal Drugs 0.000 description 1
230000009429 distress Effects 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000009510 drug design Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
238000010410 dusting Methods 0.000 description 1
244000078703 ectoparasite Species 0.000 description 1
230000000001 effect on platelet aggregation Effects 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
238000001839 endoscopy Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
230000005496 eutectics Effects 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000013265 extended release Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
229940065410 feldene Drugs 0.000 description 1
229960001419 fenoprofen Drugs 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000012065 filter cake Substances 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
229960000588 flunixin Drugs 0.000 description 1
229960000469 flunixin meglumine Drugs 0.000 description 1
238000001917 fluorescence detection Methods 0.000 description 1
230000009246 food effect Effects 0.000 description 1
235000021471 food effect Nutrition 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
229950008156 furaprofen Drugs 0.000 description 1
231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
210000000224 granular leucocyte Anatomy 0.000 description 1
208000035861 hematochezia Diseases 0.000 description 1
231100000304 hepatotoxicity Toxicity 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
WQJFIWXYPKYBTO-UHFFFAOYSA-N indole-1-acetic acid Chemical compound C1=CC=C2N(CC(=O)O)C=CC2=C1 WQJFIWXYPKYBTO-UHFFFAOYSA-N 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000007689 inspection Methods 0.000 description 1
238000009434 installation Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
229950011455 isoxepac Drugs 0.000 description 1
208000018937 joint inflammation Diseases 0.000 description 1
210000005067 joint tissue Anatomy 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
229910000464 lead oxide Inorganic materials 0.000 description 1
VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000000865 liniment Substances 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
230000007056 liver toxicity Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000037353 metabolic pathway Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229940001676 metacam Drugs 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
239000000693 micelle Substances 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
239000011707 mineral Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000004001 molecular interaction Effects 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
230000031990 negative regulation of inflammatory response Effects 0.000 description 1
231100000417 nephrotoxicity Toxicity 0.000 description 1
210000001640 nerve ending Anatomy 0.000 description 1
210000000929 nociceptor Anatomy 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
YEXPOXQUZXUXJW-UHFFFAOYSA-N oxolead Chemical compound [Pb]=O YEXPOXQUZXUXJW-UHFFFAOYSA-N 0.000 description 1
208000027753 pain disease Diseases 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
239000012466 permeate Substances 0.000 description 1
229960000482 pethidine Drugs 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
229940067157 phenylhydrazine Drugs 0.000 description 1
UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
PIDSZXPFGCURGN-UHFFFAOYSA-N pirprofen Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1N1CC=CC1 PIDSZXPFGCURGN-UHFFFAOYSA-N 0.000 description 1
229960000851 pirprofen Drugs 0.000 description 1
210000004623 platelet-rich plasma Anatomy 0.000 description 1
208000008423 pleurisy Diseases 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000035752 proliferative phase Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
230000002633 protecting effect Effects 0.000 description 1
230000009993 protective function Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
CYMJPJKHCSDSRG-UHFFFAOYSA-N pyrazolidine-3,4-dione Chemical class O=C1CNNC1=O CYMJPJKHCSDSRG-UHFFFAOYSA-N 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
239000000700 radioactive tracer Substances 0.000 description 1
238000011552 rat model Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000009467 reduction Effects 0.000 description 1
231100000628 reference dose Toxicity 0.000 description 1
238000010992 reflux Methods 0.000 description 1
229940099315 rimadyl Drugs 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
150000003870 salicylic acids Chemical class 0.000 description 1
238000007790 scraping Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
238000010956 selective crystallization Methods 0.000 description 1
230000035807 sensation Effects 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
RCOSUMRTSQULBK-UHFFFAOYSA-N sodium;propan-1-olate Chemical compound [Na+].CCC[O-] RCOSUMRTSQULBK-UHFFFAOYSA-N 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
229940086735 succinate Drugs 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical group NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
229960000894 sulindac Drugs 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
229960004492 suprofen Drugs 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000008961 swelling Effects 0.000 description 1
210000001258 synovial membrane Anatomy 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
LZNWYQJJBLGYLT-UHFFFAOYSA-N tenoxicam Chemical compound OC=1C=2SC=CC=2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 LZNWYQJJBLGYLT-UHFFFAOYSA-N 0.000 description 1
229960002871 tenoxicam Drugs 0.000 description 1
238000010257 thawing Methods 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
150000003595 thromboxanes Chemical class 0.000 description 1
229940098465 tincture Drugs 0.000 description 1
208000037816 tissue injury Diseases 0.000 description 1
229960001017 tolmetin Drugs 0.000 description 1
UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000008736 traumatic injury Effects 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
238000001262 western blot Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
238000013389 whole blood assay Methods 0.000 description 1
239000008096 xylene Substances 0.000 description 1
229910052727 yttrium Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Medicinal Preparation (AREA)

AU69321/98A 1997-05-05 1998-05-01 Cox-2 selective carprofen for treating pain and inflammation in dogs Abandoned AU6932198A (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
AU38232/02A AU773615B2 (en)	1997-05-05	2002-05-08	COX-2 selective carprofen for treating pain and inflammation in dogs

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US4563597P	1997-05-05	1997-05-05
US60045635		1997-05-05
PCT/IB1998/000662 WO1998050033A1 (en)	1997-05-05	1998-05-01	Cox-2 selective carprofen for treating pain and inflammation in dogs

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
AU38232/02A Division AU773615B2 (en)	1997-05-05	2002-05-08	COX-2 selective carprofen for treating pain and inflammation in dogs

Publications (1)

Publication Number	Publication Date
AU6932198A true AU6932198A (en)	1998-11-27

Family

ID=21939053

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU69321/98A Abandoned AU6932198A (en)	1997-05-05	1998-05-01	Cox-2 selective carprofen for treating pain and inflammation in dogs

Country Status (32)

Country	Link
EP (1)	EP0988034A1 (is)
JP (1)	JP2000513020A (is)
KR (2)	KR20010012300A (is)
CN (1)	CN1255059A (is)
AP (1)	AP9801234A0 (is)
AR (2)	AR011726A1 (is)
AU (1)	AU6932198A (is)
BG (1)	BG103852A (is)
BR (1)	BR9808720A (is)
CA (1)	CA2288759A1 (is)
DZ (1)	DZ2479A1 (is)
EA (1)	EA003696B1 (is)
GT (1)	GT199800063A (is)
HR (1)	HRP980244A2 (is)
HU (1)	HUP0001286A3 (is)
ID (1)	ID21311A (is)
IL (1)	IL132570A0 (is)
IS (1)	IS5220A (is)
MA (1)	MA26491A1 (is)
NO (1)	NO995389L (is)
NZ (1)	NZ500183A (is)
OA (1)	OA11213A (is)
PA (1)	PA8450601A1 (is)
PE (1)	PE72599A1 (is)
PL (1)	PL337003A1 (is)
SK (1)	SK148199A3 (is)
TN (1)	TNSN98059A1 (is)
TW (1)	TW590773B (is)
UY (1)	UY24989A1 (is)
WO (1)	WO1998050033A1 (is)
YU (1)	YU55899A (is)
ZA (1)	ZA983722B (is)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU764872B2 (en) *	1998-10-23	2003-09-04	Merck Frosst Canada & Co.	Combination product comprising an E-type prostaglandin ligand and a cox-2 selective inhibitor and methods of use
AU2003204888B2 (en) *	1998-05-22	2005-07-28	Pfizer Products Inc.	Treating or Preventing the Early Stages of Degeneration of Articular Cartilage or Subchondral Bone in Mammals Using Carprofen and Derivatives

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6245797B1 (en)	1997-10-22	2001-06-12	Merck & Co., Inc.	Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
US6506785B2 (en) *	1998-05-22	2003-01-14	Pfizer, Inc.	Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives
EP1637137A3 (en) *	1999-03-10	2006-07-05	G.D. Searle LLC	Method and composition for administering a cyclooxygenase-2 inhibitor to animals
WO2001034204A1 (en) *	1999-11-11	2001-05-17	Eli Lilly And Company	Oncolytic combinations for the treatment of cancer
US20020016342A1 (en) *	2000-05-15	2002-02-07	Edward Scolnick	Combination therapy using COX-2 selective inhibitor and thromboxane inhibitor and compositions therefor
US6924303B2 (en)	2000-06-13	2005-08-02	Wyeth	Analgesic and anti-inflammatory compositions containing COX-2 inhibitors
DE10032132A1 (de) *	2000-07-01	2002-01-17	Lohmann Therapie Syst Lts	Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung
CA2422803A1 (en)	2000-08-07	2002-02-14	Vanderbilt University	Detection of cox-2 activity and anandamide metabolites
US20040209959A1 (en) *	2001-07-16	2004-10-21	Edward Hogestatt	Congeners of acetaminophen and related compounds as substrates for fatty acid conjugation and their use in treatment of pain, fever and inflammation
PL2266585T3 (pl)	2003-05-07	2013-10-31	Osteologix As	Rozpuszczalne w wodzie sole stronktu do stosowania w leczeniu chorób chrząstki i/lub kości
EP1651210A1 (en) *	2003-07-31	2006-05-03	Pharmacia & Upjohn Company LLC	Dispersible formulation of an anti-inflammatory agent
US20080269310A1 (en) *	2005-05-20	2008-10-30	Adrian Paul Foster	Synergistic Combinations
CA2683415C (en)	2007-04-04	2020-12-08	Sigmoid Pharma Limited	An oral pharmaceutical composition
WO2008132707A1 (en)	2007-04-26	2008-11-06	Sigmoid Pharma Limited	Manufacture of multiple minicapsules
JP5640079B2 (ja)	2009-05-18	2014-12-10	シグモイド・ファーマ・リミテッドＳｉｇｍｏｉｄＰｈａｒｍａＬｉｍｉｔｅｄ	油滴含有組成物
BR112012002963A2 (pt)	2009-08-12	2017-10-24	Sigmoid Pharma Ltd	composições imunomoduladoras compreendendo uma matriz de polímero e uma fase oleosa
GB201020032D0 (en)	2010-11-25	2011-01-12	Sigmoid Pharma Ltd	Composition
GB201212010D0 (en)	2012-07-05	2012-08-22	Sigmoid Pharma Ltd	Formulations
GB201319791D0 (en)	2013-11-08	2013-12-25	Sigmoid Pharma Ltd	Formulations
US12109218B2 (en)	2014-12-09	2024-10-08	Aratana Therapeutics, Inc.	Compositions of grapiprant and methods for using the same
ES2907285T3 (es) *	2014-03-06	2022-04-22	Elanco Animal Health Incorporated	Composiciones de grapiprant y procedimientos de uso de las mismas
EA036036B1 (ru)	2014-11-07	2020-09-16	Сигмойд Фарма Лимитед	Композиции, содержащие циклоспорин
EP3242557A4 (en) *	2015-01-09	2018-09-05	Jaguar Health, Inc.	Methods of treating diarrhea in companion animals
JP2023520367A (ja) *	2020-03-25	2023-05-17	エスアールアイインターナショナル	リポキシゲナーゼ阻害剤
US11116737B1 (en)	2020-04-10	2021-09-14	University Of Georgia Research Foundation, Inc.	Methods of using probenecid for treatment of coronavirus infections
KR102404883B1 (ko)	2020-11-30	2022-06-07	(주)이노보테라퓨틱스	벤즈브로마론을 포함하는 켈로이드 또는 비대흉터 예방 또는 치료용 약학 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3896145A (en) *	1972-07-24	1975-07-22	Hoffmann La Roche	Carbazoles
CA1319886C (en) *	1987-02-03	1993-07-06	Alberto Ferro	Mixed micelle solutions

1998
- 1998-03-02 DZ DZ980089A patent/DZ2479A1/xx active
- 1998-04-30 TW TW087106689A patent/TW590773B/zh not_active IP Right Cessation
- 1998-05-01 PL PL98337003A patent/PL337003A1/xx unknown
- 1998-05-01 SK SK1481-99A patent/SK148199A3/sk unknown
- 1998-05-01 EA EA199900895A patent/EA003696B1/ru not_active IP Right Cessation
- 1998-05-01 CN CN98804845A patent/CN1255059A/zh active Pending
- 1998-05-01 YU YU55899A patent/YU55899A/sh unknown
- 1998-05-01 EP EP98915041A patent/EP0988034A1/en not_active Withdrawn
- 1998-05-01 JP JP10547869A patent/JP2000513020A/ja active Pending
- 1998-05-01 IL IL13257098A patent/IL132570A0/xx unknown
- 1998-05-01 ID IDP980651A patent/ID21311A/id unknown
- 1998-05-01 NZ NZ500183A patent/NZ500183A/en unknown
- 1998-05-01 WO PCT/IB1998/000662 patent/WO1998050033A1/en not_active Ceased
- 1998-05-01 KR KR1019997010252A patent/KR20010012300A/ko not_active Ceased
- 1998-05-01 AU AU69321/98A patent/AU6932198A/en not_active Abandoned
- 1998-05-01 CA CA002288759A patent/CA2288759A1/en not_active Abandoned
- 1998-05-01 HU HU0001286A patent/HUP0001286A3/hu unknown
- 1998-05-01 BR BR9808720-7A patent/BR9808720A/pt not_active IP Right Cessation
- 1998-05-01 KR KR10-2003-7005258A patent/KR20040004406A/ko not_active Ceased
- 1998-05-04 UY UY24989A patent/UY24989A1/es not_active Application Discontinuation
- 1998-05-04 AP APAP/P/1998/001234A patent/AP9801234A0/en unknown
- 1998-05-04 GT GT199800063A patent/GT199800063A/es unknown
- 1998-05-04 ZA ZA9803722A patent/ZA983722B/xx unknown
- 1998-05-04 TN TNTNSN98059A patent/TNSN98059A1/fr unknown
- 1998-05-04 PE PE1998000335A patent/PE72599A1/es not_active Application Discontinuation
- 1998-05-04 MA MA25059A patent/MA26491A1/fr unknown
- 1998-05-05 HR HR60/045,635A patent/HRP980244A2/hr not_active Application Discontinuation
- 1998-05-05 AR ARP980102089A patent/AR011726A1/es unknown
- 1998-05-05 PA PA19988450601A patent/PA8450601A1/es unknown
1999
- 1999-10-19 IS IS5220A patent/IS5220A/is unknown
- 1999-11-02 OA OA9900242A patent/OA11213A/en unknown
- 1999-11-03 BG BG103852A patent/BG103852A/xx unknown
- 1999-11-04 NO NO995389A patent/NO995389L/no not_active Application Discontinuation
2003
- 2003-04-09 AR ARP030101251A patent/AR039628A2/es unknown

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2003204888B2 (en) *	1998-05-22	2005-07-28	Pfizer Products Inc.	Treating or Preventing the Early Stages of Degeneration of Articular Cartilage or Subchondral Bone in Mammals Using Carprofen and Derivatives
AU764872B2 (en) *	1998-10-23	2003-09-04	Merck Frosst Canada & Co.	Combination product comprising an E-type prostaglandin ligand and a cox-2 selective inhibitor and methods of use

Also Published As

Publication number	Publication date
EP0988034A1 (en)	2000-03-29
TW590773B (en)	2004-06-11
EA003696B1 (ru)	2003-08-28
EA199900895A1 (ru)	2000-06-26
OA11213A (en)	2003-07-14
BG103852A (en)	2000-06-30
MA26491A1 (fr)	2004-12-20
WO1998050033A1 (en)	1998-11-12
IL132570A0 (en)	2001-03-19
CA2288759A1 (en)	1998-11-12
PE72599A1 (es)	1999-08-12
AR039628A2 (es)	2005-03-02
UY24989A1 (es)	2001-10-25
HRP980244A2 (en)	1999-02-28
NZ500183A (en)	2002-04-26
AR011726A1 (es)	2000-08-30
SK148199A3 (en)	2001-09-11
ID21311A (id)	1999-05-20
ZA983722B (en)	1999-11-04
TNSN98059A1 (fr)	2005-03-15
AP9801234A0 (en)	1999-11-04
BR9808720A (pt)	2000-07-11
CN1255059A (zh)	2000-05-31
IS5220A (is)	1999-10-19
PA8450601A1 (es)	2000-05-24
KR20040004406A (ko)	2004-01-13
KR20010012300A (ko)	2001-02-15
HUP0001286A3 (en)	2000-12-28
DZ2479A1 (fr)	2003-02-01
JP2000513020A (ja)	2000-10-03
NO995389D0 (no)	1999-11-04
NO995389L (no)	2000-01-04
HUP0001286A2 (hu)	2000-11-28
PL337003A1 (en)	2000-07-31
YU55899A (sh)	2003-08-29
GT199800063A (es)	1999-10-26

Publication	Publication Date	Title
AU6932198A (en)	1998-11-27	Cox-2 selective carprofen for treating pain and inflammation in dogs
AU702662B2 (en)	1999-02-25	Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic acitivities
US6399647B2 (en)	2002-06-04	Amide derivatives for antiangiogenic and/or antitumorigenic use
US8389563B2 (en)	2013-03-05	C-substituted diindolylmethane compositions and methods for the treatment of multiple cancers
FI66860B (fi)	1984-08-31	Foerfarande foer framstaellning av terapeutiskt anvaendbara 3-1-imidazolylalkyl)indolderivat
US8519005B2 (en)	2013-08-27	Compositions and methods to prevent toxicity of antiinflammatory agents and enhance their efficacy
ITMI980146A1 (it)	1999-07-28	Sali dell'acido (r) 2-(3-benzoilfenil) propionico e loro composizioni farmaceutiche
JP2006500378A (ja)	2006-01-05	二元ＰＰＡＲα／γアゴニストとアンギオテンシンＩＩのＩ型受容体アンタゴニストを使用する併用療法
US20030212123A1 (en)	2003-11-13	COX-2 selective carprofen for treating pain and inflammation in dogs
CN102652135A (zh)	2012-08-29	脂肪酸酰胺水解酶的含氮杂环抑制剂
JP4874489B2 (ja)	2012-02-15	Ｃｏｍｔ阻害剤の鎮痛剤としての用途
JP2001514655A (ja)	2001-09-11	アルツハイマー病予防へのｒ−ｎｓａｉｄ’ｓの利用
AU773615B2 (en)	2004-05-27	COX-2 selective carprofen for treating pain and inflammation in dogs
US5639773A (en)	1997-06-17	Ocular hypotensive agent
CN101563321B (zh)	2012-05-30	4-(杂环基)烷基-n-(芳基磺酰基)吲哚化合物及其作为5-ht6配体的用途
NZ516914A (en)	2003-08-29	Compositions containing COX-2 selective carprofen and derivatives thereof for treating pain and inflammation in dogs
CA2281050A1 (en)	2000-02-29	Nitric oxide releasing oxindole prodrugs for analgesic, anti-inflammatory and disease-modifying use
JP2004511436A (ja)	2004-04-15	失禁用医薬
CZ9903896A3 (cs)	2001-05-16	Léčivo, farmaceutický přípravek a souprava pro léčení nebo prevenci bolesti a zánětlivých procesů
US20150065486A1 (en)	2015-03-05	Methods for treating polycystic kidney disease
JP2007529510A (ja)	2007-10-25	細胞接着を抑制するメチマゾール誘導体及び互変異性環状チオン
HK1025261A (en)	2000-11-10	Cox-2 selective carprofen for treating pain and inflammation in dogs
TW200908964A (en)	2009-03-01	Use of HDAC inhibitors for the treatment of gastrointestinal cancers
MXPA99008048A (en)	2000-08-01	Oxynolic developers oxidonitric releases for analgesic, anti-inflammatory use and as a sick modifier
HK1059378B (en)	2010-09-10	Analgesic and anti-inflammatory compositions containing cox-2 inhibitors

Legal Events

Date	Code	Title	Description
2002-06-13	MK5	Application lapsed section 142(2)(e) - patent request and compl. specification not accepted

AU6932198A - Cox-2 selective carprofen for treating pain and inflammation in dogs - Google Patents

Info

Links

Classifications

Landscapes

Priority Applications (1)

Applications Claiming Priority (3)

Related Child Applications (1)

Publications (1)

Family

ID=21939053

Family Applications (1)

Country Status (32)

Cited By (2)

Families Citing this family (26)

Family Cites Families (2)

Cited By (2)

Also Published As

Similar Documents

Legal Events